In the subsequent phase III CheckMate 143 trial of nivolumab (NCT02017717), no significant improvement was observed in the median survival and 12-month survival rates of recurrent GBM treated with a PD-1 inhibitor compared with the vascular endothelial growth factor A (VEGF-A) inhibitor bevacizumab (7). The gene discussed is VEGFA; the disease is glioblastoma.